UB#INBIORC2611D

Innovent Biologics Announces Early Results of IBI363 for Advanced NSCLC

Innovent Biologics to Present Phase 3 Trial Results of Mazdutide at 2026 ADA Scientific Sessions

Innovent Biologics' IBI363 Receives Breakthrough Therapy Designation and Prepares for Phase III Clinical Trial

Goldman Sachs Raises Earnings Forecast and Target Price for Innovent Biologics

CICC Maintains Overweight Industry Rating for Innovent Biologics, Anticipates Continued Revenue Growth

Innovent Biologics Q1 2026 Revenue Exceeds RMB 3.8 Billion with YoY Growth of Over 50%

BofA Securities Reports: CStone Pharmaceuticals Sees Strong February Drug Sales

Innosyn Biologics to Present Clinical Data on IBI363 and TYVYT at the 2026 ASCO Annual Meeting

Ede Ronald Hao Xi reduced holdings of Innovent Biologics to 1 million shares

Innovative Drug Margetide's Phase II Clinical Trial Results Published in Cell Journal

CICC Report Analyzes Innovent Biologics 2025 Performance and Provides Rating Recommendations

UBS Cuts CSB Biopharma EPS Forecast but Maintains Buy Rating

Citi Raises Rating and Target Price for Innovent Biologics

Goldman Sachs Report: Innovent Biologics Surpassed Revenue Expectations in H2 2022

INNOVENT BIO released FY2025 9 Months Earnings on March 26, 2026 (BJT) with actual revenue of HKD 6.446 B and EPS of HKD 0.5305

INNOVENT BIO released FY2025 Q3 earnings on March 26 (BJT), actual revenue HKD 3.874 B, actual EPS HKD -0.0066

INNOVENT BIO released FY2025 Q4 earnings on March 26 After-Market (BJT), actual revenue HKD 3.941 B, actual EPS HKD -0.0067

INNOVENT BIO released FY2025 Annual Earnings on March 26 After-Market (BJT), Actual Revenue: HKD 14.25 B (Forecast: HKD 14.83 B), Actual EPS: HKD 0.5136 (Forecast: HKD 1.07)

Innovent Biologics Announces Profitable Year, Reversing Previous Losses

Innovent Biologics Clarifies Strategic Cooperation Agreement Not an Acquisition

JOLIMARK

PANGAEA CONNECT

WEILI HOLDINGS

MAN YUE TECH

SMIT

BJ DIGITAL

FY FINANCIAL

NEW GONOW RV

RADIANCE HLDGS

PERFECTECH INTL

01801

516500

520690

159837

159570

588250

517110

CSC Financial analyst maintained a Buy rating on Innovent Biologics yesterday and set a price target of HK$137.51.Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds Innovent Biologics has an analyst consensus of Strong Buy, with a price target consensus of HK$118.69.

Tip Ranks

INNOVENT BIO

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Huaan Hang Seng Biotech ETF

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

Innovent Biologics (IVBXF) Receives a Buy from CSC Financial

Innovent Biologics has made USD690 million in structured note investments with JPMorgan and UBS, including JPM Notes I for USD280 million and UBS Notes for USD280 million. These transactions are structured as non-shareholder-approval under Hong Kong Listing Rules, highlighting their significance for the company's financial profile. The latest analyst rating for Innovent Biologics (HK:1801) is a Buy with a price target of HK$113.00.

JPMorgan Chase

UBS Group AG

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Innovent Biologics Makes USD690 Million Structured Note Investments With JPMorgan and UBS

588130

159316

Innovent Biologics presented updated data on IBI363, a PD-1/IL-2α-bias bispecific fusion protein, at the 2026 ASCO Annual Meeting. The Phase 1 PoC study showed robust survival benefits in advanced immunotherapy-resistant non-small cell lung cancer (NSCLC), with a favorable safety profile. IBI363 demonstrated a median overall survival of 18.2 months in squamous NSCLC and 15.2 months in adenoNSCLC. A global Phase 3 study for IO-resistant squamous NSCLC is set to begin, pending regulatory communications.

MorningStar

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Tianhong CNI BIOMEDICINE ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

First Trust NYSE Arca Biotech Index Fd

Penghua CSI HK Connect Health Care Composite ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

HUTCHMED and Innovent Biologics have received NMPA approval for the ELUNATE-TYVYT combination to treat advanced renal cell carcinoma in patients who failed prior therapies. The approval is based on Phase 3 trial results showing a 63% reduction in disease progression risk and a median progression-free survival of 22.2 months. This marks the 10th indication for TYVYT in China, highlighting the importance of targeted and immunotherapy combinations in oncology.

nasdaq

Hutchmed China

HUTCHMED

Eli Lilly

Takeda Pharmaceutical Company

Nasdaq

Hutchmed And Innovent Secure NMPA Approval For ELUNATE-TYVYT Combo In Advanced Renal Cell Carcinoma

09927

00501

09868

09926

06082

06869

09888

01024

06613

SERES(09927) rose 5.09%, with a trading turnover 218.1 Million HKD, and a year-to-date fell 33.9%. OMNIVISION(00501) rose 5%, with a trading turnover 239.8 Million HKD, and a year-to-date fell 9.7%. BIREN TECH(06082) fell 7.69%, with a trading turnover 339.2 Million HKD, and a year-to-date rose 138.8%. YOFC(06869) fell 6.84%, with a trading turnover 3.4 Billion HKD, and a year-to-date rose 316.2%.

- The Hang Seng Index fell by 1.03%, with a year-to-date decline of 1%.  
- The Hang Seng Tech Index decreased by 2.15%, accumulating a 13.5% loss for the year.  
- Notable movements include Sai Liu Si rising by 5.09% despite a 33.9% year-to-date drop, while Wall Group and Biran Technology saw gains and losses, respectively, throughout the year.

Top Gainers&Losers

SERES

OMNIVISION

XPENG-W

AKESO

BIREN TECH

YOFC

BIDU-SW

KUAISHOU-W

Lens

Top 5 HK Stock Gainers/Losers (>100B) (5.21)

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

prnewswire

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

02509

603259

WXXWY

588860

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

AASTOCKS News

QYUNS-B

WuXi AppTec

WuXi Biologics

WUXI APPTEC

SKB BIO

WUXI BIO

TEDA BIOMEDICAL

WUXI XDC

ICBCCS SSE STAR Biology and Medicine ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

CICC analyst maintained a Buy rating on Innovent Biologics yesterday and set a price target of HK$118.30.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Innovent Biologics is a Strong Buy with an average price target of HK$118.15.

CICC

CICC Sticks to Their Buy Rating for Innovent Biologics (IVBXF)

G Sachs has raised the target price for INNOVENT BIOto HKD105.94 following a strong 1Q26 performance, where product revenue exceeded RMB3.8 billion, up over 50% YoY. This surpassed the broker's forecast of RMB3.5 billion, driven by product portfolio expansion. G Sachs also increased EPS forecasts for 2026 to 2028 and maintained a Buy rating. Key data releases in June at the ADA and ASCO conferences are anticipated to attract market attention.

Goldman Sachs

GS Hldg R

G Sachs Raises INNOVENT BIO  TP to HKD105.94; 1Q Product Sales Beat

UB#INBIORC2611D(53958.HK)